Dear Editor:
Several issues around rule-out strategies utilising low concentrations of highsensitivity cardiac troponin (hs-cTn) assays taken at presentation to the Emergency Department (ED) remain unexplored. Firstly, large-scale analyses investigating cutoff concentrations for hs-cTnI (Abbott Architect) < 99 th percentile, have failed to investigate outcomes which incorporate the full spectrum of clinically relevant acute coronary syndromes, namely emergency revascularization (1, 2) . Secondly, whether these strategies work with the hs-cTnT (Roche Elecsys) assay are under-explored.
Finally, the impact of laboratory rounding (ie. rounding the reported value up or down to the next whole integer depending on the exact post-decimal point value e.g.
4.5ng/L to 5ng/L) upon diagnostic performance at low cut-off concentrations, and how this effects the proportion of patients potentially eligible for early discharge, remains unknown.
In this post-hoc analysis of a prospectively recruited cohort we aimed to establish the diagnostic performance of a single hs-cTnT result taken at ED presentation in patients with a non-ischemic ECG, using the LoD and additional cut-off concentrations <99 th percentile, and also the impact of laboratory rounding.
The methods and results of the primary analysis have been published previously, including reporting of diagnostic accuracy at the LoD for hs-cTnT at ED presentation We demonstrate that hs-cTnT taken at ED presentation can, using a cut-off of <5ng/L (LoD), identify >20% of patients as potentially suitable for discharge. At this cut-off, for the outcome of MACE, diagnostic performance may fall to levels below that which is clinically acceptable (5). However, it should be noted that the composite outcome of MACE includes revascularization which, although important, is a subjective outcome. We also demonstrate that cut-off values >LoD may not have adequate diagnostic performance for clinical implementation. Laboratory rounding may significantly reduce the proportion of patients potentially suitable for early discharge using the LoD cut-off.
Importantly, we have not analyzed those patients presenting early after symptom onset. The diagnostic performance of low cut-off concentrations has been shown to fall in this subgroup (1). Futhermore, we selected patients without new onset ECG changes diagnostic of ischemia. Therefore, the population selected for this analysis were likely to be at lower risk when compared to prior studies, and diagnostic performance may be overestimated as a result.
Given the medicolegal implications for missed MACE, clinicians must carefully consider whether a LoD strategy is ready for clinical implementation. In particular,
were clinicians to make a discharge decision based on an undetectable troponin, full consideration should be given to time from symptom onset, further risk-stratification, and the need for advanced cardiac testing.
Whether strategies that utilize low cut-off concentrations of hs-cTn can be successfully implemented into clinical practice remains unknown. Further studies are required to determine the clinical and cost effectiveness of such strategies. 
